GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » Revenue

ThermoGenesis Holdings (STU:THR) Revenue : €8.76 Mil (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings Revenue?

ThermoGenesis Holdings's revenue for the three months ended in Dec. 2023 was €2.21 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €8.76 Mil. ThermoGenesis Holdings's Revenue per Share for the three months ended in Dec. 2023 was €0.61. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €4.20.

Warning Sign:

ThermoGenesis Holdings Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of ThermoGenesis Holdings was -79.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -61.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was -55.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was -53.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, ThermoGenesis Holdings's highest 3-Year average Revenue per Share Growth Rate was 36.50% per year. The lowest was -61.40% per year. And the median was -3.90% per year.


ThermoGenesis Holdings Revenue Historical Data

The historical data trend for ThermoGenesis Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Revenue Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.74 8.01 8.23 9.90 8.66

ThermoGenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 2.40 2.10 2.06 2.21

Competitive Comparison of ThermoGenesis Holdings's Revenue

For the Medical Devices subindustry, ThermoGenesis Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Revenue falls into.



ThermoGenesis Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (STU:THR) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


ThermoGenesis Holdings Revenue Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (STU:THR) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.